ESCJX Mutual Fund

ESCJX Mutual Fund

NAV$16.79
See how much of ESCJX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Aug 31, 2026

Net Assets
$103M
Expense Ratio
0.88%
Dividend Yield (Current)
-
Holdings
102
Inception Date
Jul 11, 2022
Fund Family
1290 Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+5.43%
1 Year+3.88%
3 Year+26.79%

Asset Allocation

Stocks: 96.53%
Cash: 2.59%
Other: 0.89%
See how much of ESCJX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
KNSAKiniksa Pharmaceuticals, Ltd.2.74%
ADPTAdaptive Biotechnologies2.45%
JIMXXJpmorgan Prime Money2.33%
CECOCeco Environmental Corp Common Stock Usd 0.012.24%
TVTXTravere Therapeutics Inc1.97%
Top 10 Concentration: 20.22%Report Date: Aug 31, 2026
Download all 102 holdings for ESCJX
CSV export with sector, industry & share changes
Get CSV

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

ESCJX Mutual Fund Overview

ESCJX Mutual Fund (1290 Essex Small Cap Growth Fund Class I) is managed by 1290 Funds with $103.1M in net assets. ESCJX expense ratio is 0.88%, holding 102 positions across sectors including Information Technology, Industrials, Health Care. Inception date: 2022-07-11.

ESCJX performance shows a YTD return of 5.43%. The 1-year return is 3.88%.

ESCJX top holdings include Kiniksa Pharmaceuticals, Ltd. (2.7%), Adaptive Biotechnologies (2.5%), Jpmorgan Prime Money (2.3%), Ceco Environmental Corp Common Stock Usd 0.01 (2.2%), Travere Therapeutics Inc (2.0%). Go to all ESCJX holdings, ESCJX sectors, or ESCJX dividends.

ESCJX can be compared against other funds. Use ESCJX overlap to find shared positions, or ESCJX vs another fund for a side-by-side view. ESCJX alternatives are available via the screener, along with tax-loss harvesting opportunities.